Friederike Liesche1, Mathias Lukas2,3,4, Christine Preibisch5, Kuangyu Shi2,6, Jürgen Schlegel1, Bernhard Meyer7, Markus Schwaiger2, Claus Zimmer5, Stefan Förster2, Jens Gempt7, Thomas Pyka8,9. 1. Department of Neuropathology, Institute of Pathology, Technische Universität München, Trogerstraße 18, 81675, Munich, Germany. 2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. 3. Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. 4. Siemens Healthcare GmbH, Berlin, Germany. 5. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. 6. Department of Nuclear Medicine, Universität Bern, Hochschulstraße 6, 3012, Bern, Switzerland. 7. Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. 8. Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. thomas.pyka@tum.de. 9. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, Munich, Germany. thomas.pyka@tum.de.
Abstract
PURPOSE: To investigate the in vivo correlation between 18F-fluoroethyl-tyrosine (18F-FET) uptake and amino acid transporter expression and vascularization in treatment-naive glioblastomas. METHODS: A total of 43 stereotactic biopsies were obtained from 13 patients with suspected glioblastoma prior to therapy. All patients underwent a dynamic 18F-FET PET/MRI scan before biopsy. Immunohistochemistry was performed using antibodies against SLC7A5 (amino acid transporter), MIB-1 (Ki67, proliferation), CD31 (vascularization) and CA-IX (hypoxia). The intensity of staining was correlated with 18F-FET uptake and the dynamic 18F-FET uptake slope at the biopsy target point. RESULTS: In all patients, the final diagnosis was IDH-wildtype glioblastoma, WHO grade IV. Static 18F-FET uptake was significantly correlated with SLC7A5 staining (r = 0.494, p = 0.001). While the dynamic 18F-FET uptake slope did not show a significant correlation with amino acid transporter expression, it was significantly correlated with the number of CD31-positive vessels (r = -0.350, p = 0.031), which is line with earlier results linking 18F-FET kinetics with vascularization and perfusion. Besides, static 18F-FET uptake also showed correlations with CA-IX staining (r = 0.394, p = 0.009) and CD31 positivity (r = 0.410, p = 0.006). While the correlation between static 18F-FET uptake and SLC7A5 staining was confirmed as significant in multivariate analysis, this was not the case for the correlation with CD31 positivity, most likely because of the lower effect size and the relatively low number of samples. No significant correlation between 18F-FET uptake and Ki67 proliferation index was observed in our cohort. CONCLUSION: Our results support the findings of preclinical studies suggesting that specific 18F-FET uptake in glioblastomas is mediated by amino acid transporters. As proposed previously, dynamic 18F-FET parameters might be more influenced by perfusion and therefore related to properties of the tumour neovascularization.
PURPOSE: To investigate the in vivo correlation between 18F-fluoroethyl-tyrosine (18F-FET) uptake and amino acid transporter expression and vascularization in treatment-naive glioblastomas. METHODS: A total of 43 stereotactic biopsies were obtained from 13 patients with suspected glioblastoma prior to therapy. All patients underwent a dynamic 18F-FET PET/MRI scan before biopsy. Immunohistochemistry was performed using antibodies against SLC7A5 (amino acid transporter), MIB-1 (Ki67, proliferation), CD31 (vascularization) and CA-IX (hypoxia). The intensity of staining was correlated with 18F-FET uptake and the dynamic 18F-FET uptake slope at the biopsy target point. RESULTS: In all patients, the final diagnosis was IDH-wildtype glioblastoma, WHO grade IV. Static 18F-FET uptake was significantly correlated with SLC7A5 staining (r = 0.494, p = 0.001). While the dynamic 18F-FET uptake slope did not show a significant correlation with amino acid transporter expression, it was significantly correlated with the number of CD31-positive vessels (r = -0.350, p = 0.031), which is line with earlier results linking 18F-FET kinetics with vascularization and perfusion. Besides, static 18F-FET uptake also showed correlations with CA-IX staining (r = 0.394, p = 0.009) and CD31 positivity (r = 0.410, p = 0.006). While the correlation between static 18F-FET uptake and SLC7A5 staining was confirmed as significant in multivariate analysis, this was not the case for the correlation with CD31 positivity, most likely because of the lower effect size and the relatively low number of samples. No significant correlation between 18F-FET uptake and Ki67 proliferation index was observed in our cohort. CONCLUSION: Our results support the findings of preclinical studies suggesting that specific 18F-FET uptake in glioblastomas is mediated by amino acid transporters. As proposed previously, dynamic 18F-FET parameters might be more influenced by perfusion and therefore related to properties of the tumour neovascularization.
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: David Izquierdo-Garcia; Adam E Hansen; Stefan Förster; Didier Benoit; Sylvia Schachoff; Sebastian Fürst; Kevin T Chen; Daniel B Chonde; Ciprian Catana Journal: J Nucl Med Date: 2014-10-02 Impact factor: 10.057
Authors: Sydney M Evans; Kevin W Jenkins; H Isaac Chen; W Timothy Jenkins; Kevin D Judy; Wei-Ting Hwang; Robert A Lustig; Alexander R Judkins; M Sean Grady; Stephen M Hahn; Cameron J Koch Journal: Transl Oncol Date: 2010-06-01 Impact factor: 4.243
Authors: M Kunz; N Thon; S Eigenbrod; C Hartmann; R Egensperger; J Herms; J Geisler; C la Fougere; J Lutz; J Linn; S Kreth; A von Deimling; J C Tonn; H A Kretzschmar; G Pöpperl; F W Kreth Journal: Neuro Oncol Date: 2011-02-03 Impact factor: 12.300
Authors: Tony Lahoutte; Vicky Caveliers; Simone M R Camargo; Raffaella Franca; Tamara Ramadan; Emilija Veljkovic; John Mertens; Axel Bossuyt; François Verrey Journal: J Nucl Med Date: 2004-09 Impact factor: 10.057
Authors: Florian Stockhammer; Michail Plotkin; Holger Amthauer; Frank K H van Landeghem; Christian Woiciechowsky Journal: J Neurooncol Date: 2008-06 Impact factor: 4.130
Authors: Otto M Henriksen; Adam E Hansen; Aida Muhic; Lisbeth Marner; Karine Madsen; Søren Møller; Benedikte Hasselbalch; Michael J Lundemann; David Scheie; Jane Skjøth-Rasmussen; Hans S Poulsen; Vibeke A Larsen; Henrik B W Larsson; Ian Law Journal: Eur J Nucl Med Mol Imaging Date: 2022-07-30 Impact factor: 10.057
Authors: Eike Steidl; Karl-Josef Langen; Sarah Abu Hmeidan; Nenad Polomac; Christian P Filss; Norbert Galldiks; Philipp Lohmann; Fee Keil; Katharina Filipski; Felix M Mottaghy; Nadim Jon Shah; Joachim P Steinbach; Elke Hattingen; Gabriele D Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2020-11-26 Impact factor: 9.236
Authors: S Schön; J Cabello; F Liesche-Starnecker; M Molina-Romero; P Eichinger; M Metz; I Karimov; C Preibisch; J Keupp; A Hock; B Meyer; W Weber; C Zimmer; T Pyka; I Yakushev; J Gempt; B Wiestler Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-17 Impact factor: 9.236
Authors: K J Paprottka; S Kleiner; C Preibisch; F Kofler; F Schmidt-Graf; C Delbridge; D Bernhardt; S E Combs; J Gempt; B Meyer; C Zimmer; B H Menze; I Yakushev; J S Kirschke; B Wiestler Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-25 Impact factor: 9.236